Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DRNA

Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis

Dicerna Pharmaceuticals logo

About Dicerna Pharmaceuticals Stock (NASDAQ:DRNA)

Advanced Chart

Key Stats

Today's Range
$38.22
$38.22
50-Day Range
$37.81
$38.25
52-Week Range
$19.06
$40.14
Volume
N/A
Average Volume
1.34 million shs
Market Capitalization
$2.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive DRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DRNA Stock News Headlines

Arrowhead Pharmaceuticals (NASDAQ: ARWR)
Gold buying hits 4-year high
The perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an epic bull rally in gold. JP Morgan and Goldman Sachs have a price target of $4,000. My research tells me gold could surpass $5,000 in the coming months. Folks using a very specific gold strategy since the 80s could have made more than 60 TIMES their money. Today, you can take advantage of a similar setup for around $10
DRNA Jan 2022 22.500 call
DRNA Jul 2022 40.000 call(CONTR
See More Headlines

DRNA Stock Analysis - Frequently Asked Questions

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) issued its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.19. The biopharmaceutical company had revenue of $62.95 million for the quarter, compared to analysts' expectations of $58.83 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Marvell Technology (MRVL), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and PayPal (PYPL).

Company Calendar

Last Earnings
11/09/2021
Today
7/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRNA
Employees
302
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$112.75 million
Pretax Margin
-63.82%

Debt

Sales & Book Value

Annual Sales
$164.31 million
Price / Cash Flow
N/A
Book Value
$1.84 per share
Price / Book
20.77

Miscellaneous

Free Float
70,160,000
Market Cap
$2.99 billion
Optionable
Optionable
Beta
0.80

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:DRNA) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners